Moderna, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Moderna, Inc. (MRNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $86.02 per share for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2021-11-04
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $75.13, a 442.85% increase year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $13.84, a 13.82% increase year-over-year.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $12.16.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $19.30, a 70.04% increase from fiscal 2019.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $11.35, a 21.65% increase from fiscal 2018.
- Moderna, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $9.33.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2021-09-30 | $86.02 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $76.63 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $75.13 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $19.30 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $18.10 10-Q · filed 2020-10-30 | |||
| 2020-06-30 | $15.38 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $13.84 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $11.35 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $11.71 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $11.87 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $12.16 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $9.33 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |